Tumor-infiltrating immune cells can be conditioned by molecules released within the microenvironment to thwart antitumor immune responses, thereby facilitating tumor growth. Among immune cells, neutrophils play an important protumorigenic role by favoring neoangiogenesis and/or by suppressing antitumor immune responses. Tumor-derived oxysterols have recently been shown to favor tumor growth by inhibiting dendritic cell migration toward lymphoid organs. We report that tumor-derived oxysterols recruit protumor neutrophils in a liver X receptor (LXR)-independent, CXCR2-dependent manner, thus favoring tumor growth by promoting neoangiogenesis and immunosuppression. We demonstrate that interfering with the oxysterol-CXCR2 axis delays tumor growth and prolongs the overall survival of tumor-bearing mice. These results identify an unanticipated protumor function of the oxysterol-CXCR2 axis and a possible target for cancer therapy.
Tumor formation is the result of molecular al terations involving cellular regulators (Hanahan and Weinberg, 2011) as well as the ability of tumor cells to affect the tumor microenviron ment by smoldering inflammation (de Visser et al., 2006; Mantovani et al., 2008) or even taking advantage of inflammation to grow and metas tasize (Zitvogel et al., 2006; Grivennikov et al., 2010) . Indeed, targeted therapies aimed to in hibit molecular alterations in tumor cells even though inducing antitumor responses have improved overall survival only slightly, indicat ing that antitumor strategies comprehensive of drugs targeting molecular as well as microen vironment alterations might be more effective Each symbol corresponds to a single experiment, and the line represents the mean value (*, P < 0.05; **, P < 0.01; ***, P < 0.0001). RLA, relative luciferase activity. (B) Spectrum derived from 1 mM hydroxycholesterol mix solution (containing 22R, 22S, 25, 27, 19, 7, and 4-HC). The molecular mass for the mix of hydroxycholesterols is 402.67 kD. The collision (Vanneman and Dranoff, 2012) . Tumor microenvironment is composed of various cell types, including tumorassociated macrophages endowed with phenotypes and functions of alternatively activated or M2 macrophages (i.e., expressing IL10, TGF, ARG1, and mannose receptor; Mantovani and Sica, 2010) , which have been shown to promote tumor initia tion/formation through the induction of immune suppres sion, matrix remodeling, and angiogenesis (Murdoch et al., 2008) , and the heterogeneous CD11b + Gr1 + myeloid cells, also termed myeloidderived suppressor cells, comprising im mature myeloid progenitors for neutrophils, monocytes, and DCs (Gabrilovich and Nagaraj, 2009 ). CD11b + Gr1 + myeloid cells are present in the tumor as well as in bone marrow, pe ripheral blood, and spleen of tumorbearing mice (Bronte and Zanovello, 2005) . In particular, the immature CD11b + Gr1 + bone marrow-derived cells, as well as the CD11b high Gr1 high Ly6G + neutrophils, have been recognized as playing an im portant protumorigenic role by promoting neoangiogenesis (Yang et al., 2004) through the release of MMP9 (Nozawa et al., 2006) and Bv8 (Shojaei et al., 2008) , thus mediating re fractoriness to antiVEGF therapy (Shojaei et al., 2007a) . Neu trophils have also been shown to suppress antitumor immune responses (Fridlender et al., 2009; De Santo et al., 2010) .
Several tumorderived molecules induce immune sup pression by affecting tumorinfiltrating immune cells (Vesely et al., 2011) . Some of these molecules are intermediate or final products of the cellular metabolism, such as kynurenine, which, alone or together with the depletion of tryptophan, has been reported to promote T cell anergy (Mellor et al., 2003) . Similarly, it has been shown that the increased metab olism of larginine by myeloid cells can result in the impair ment of lymphocyte responses to tumor cells (Bronte and Zanovello, 2005) . Other metabolic pathways have recently emerged as protumorigenic. Products of lipid and cholesterol metabolism have been demonstrated to damage the function of DC both in mouse and in human tumor models. As an example, lipidloaded DCs are not able to effectively stimu late allogeneic T cells or to present tumorassociated anti gens as the result of a reduced antigen processing capability (Herber et al., 2010) .
Liver X receptor (LXR) ligands, also named oxysterols, are involved in cholesterol homeostasis (Repa and Mangelsdorf, 2000) and in modulating immune responses (Bensinger and Tontonoz, 2008) . The oxysterol 7,25HC, which is unable to activate LXRs, has recently been involved in B cell migra tion to follicles of lymphoid organ through the engagement of EBI2 receptor (Hannedouche et al., 2011; Liu et al., 2011) . We have recently shown that LXR ligands/oxysterols are re leased by cancer cells and inhibit CCR7 expression on ma turing DCs, therefore dampening DC migration to draining lymph nodes and antitumor immune responses (Villablanca et al., 2010) . Indeed, tumor cells engineered to express the oxy sterol inactivating enzyme sulfotransferase 2B1b (SULT2B1b; Fuda et al., 2007) , fail to activate LXRs in vitro and are de layed or rejected when infused in immunocompetent mice (Villablanca et al., 2010) . Whether tumorderived LXR ligands/ oxysterols are endowed with other protumorigenic functions, thus favoring the formation of hostile microenvironments for immune cells, remains elusive.
Here, we show that tumorderived oxysterols contribute to recruit neutrophils in a CXCR2dependent manner within tumor microenvironment, thus favoring neoangiogenesis and/or immunosuppression and tumor growth. Importantly, we show that oxysterol inactivation, as well as CXCR2 in activation, controls tumor growth, thus identifying a new protumor role of oxysterols and a new therapeutic target for cancer patients.
RESULTS

Functional inactivation of tumor-derived LXR ligands/ oxysterols associates with lower levels of CD11b high Gr1 high myeloid cells infiltrating tumors
Several mouse tumors release LXR ligands, as evaluated by a luciferasebased assay measuring LXR activation (Fig. 1 A) . However, the species of LXR ligands produced by these tumors, as well as their possible effects on tumorinfiltrating immune cells other than DCs (Villablanca et al., 2010) , are not known.
To identify the hydroxycholesterol species released by tumor cells, we performed solidphase extraction of conditioned me dium (CM) from the T cell lymphoma RMA and NIH3T3 cells, the latter being unable to activate LXR (unpublished data), followed by mass spectrometry (MS) analysis. Cholesterol oxidation products share a common fragmentation pattern The concentration of hydroxycholesterols with respect to ml of media (µmol/ml) is reported. Results (D and E) are representative of three different experiments (mean ± SEM). *, P < 0.05 versus medium; **, P < 0.01 versus NIH-3T3-CM. (F and G) HPLC chromatograms of seven single hydroxycholesterol standards (F) and of hydroxycholesterols from RMA-CM (G). Two main hydroxysterols are identified on the basis of the retention time: the 22-HC and 27-HC in a ratio of 4:1. (H) qRT-PCR for Cyp11a1, Cyp27a1, and Ch25h transcripts expression in RMA relative to NIH-3T3. Results are representative of two experiments (mean ± SEM). *, P < 0.05; ***, P < 0.0001. (I and J) CM from human melanomas (I), and lung and kidney (J) tumors after a few in vitro passages (3-4 passages) were collected and tested for the presence of LXR ligands by LXR luciferase-based reporter assay. Each symbol corresponds to a single tumor CM tested and the line represents the mean value. **, P < 0.01; ***, P < 0.0001. (K) qRT-PCR analysis for Abcg1 and Srebp-1c mRNA expression in myeloid cells from bone marrow of wild-type (WT), RMA-Mock-, and RMA-SULT2B1b-bearing mice (n = 3; mean ± SEM). *, P < 0.05. Results are representative of three independent experiments.
in agreement with the presence of hydroxycholesterols in the fetal calf serum used to supplement the culture media (Pie and Seillan, 1992) . Nevertheless, we observed a higher con tent of hydroxycholesterols in RMACM than in culture medium and in NIH3T3CM (10 and 5.5fold, respectively). In particular, the concentrations of hydroxycholesterols, re ported as relative abundance of the three molecular ions (m/z 385, 369, and 367), using 1 mM hydroxycholesterol mix ture as a standard (Fig. 1 D) , were 0.195 ± 0.012 µmol/ml, 0.357 ± 0.027 µmol/ml, and 1.973 ± 0.34 µmol/ml for cul ture medium, NIH3T3, and RMA, respectively (Fig. 1 E) . Two main hydroxycholesterols could be identified on the basis of the retention time determined by HPLC analysis using a series of standards (Fig. 1 F) : 22HC (22hydroxycholesterol) and 27HC in a ratio of 4:1 (Fig. 1 G) . Accordingly, we found that RMA cells expressed transcripts for Cyp11a, Cyp27a1, and Ch25h enzymes, which are involved in the synthesis of 22RHC, 27HC, and 25HC, respectively (Björkhem, 2002; Murphy and Johnson, 2008; Mast et al., 2011; Fig. 1 H) . In similar experiments, we detected 24SHC in the Lewis lung carcinoma (LLC)-CM, and the expression of Cyp46a1 tran script by LLC cells (unpublished data). Moreover, we detected LXR ligands/oxysterols in tumorCM from some freshly isolated human tumor cells (Fig. 1, I and J). In particular, we detected the oxysterols 22HC and 24SHC in CM from 005mel and MR300 tumor cells (unpublished data). Nota bly, we detected in vivo a signature of LXR activation (Abcg1 and Srebp-1c upregulation) in cells of the myeloid compart ment purified from the bone marrow of RMAbearing mice, but not from mice bearing RMASULT2B1b tumors, which are unable to produce active LXR ligands/oxysterols (Fig. 1 K) . These experiments indicate that tumors may release amounts of oxysterols sufficient to reach and activate LXRsensitive cells located in organs far away from the tumor.
To evaluate whether these oxysterols were affecting other immune cells besides DCs in the tumor microenvironment, we analyzed by FACS tumorinfiltrating immune cells from 14d established RMA mocktransduced (RMAMock) and RMASULT2B1b and found a higher percentage and num ber of CD11b high Gr1 high cells infiltrating RMAMock tumors (Fig. 2 , A-C and E). We found a similar difference in terms of CD11b high Gr1 high cells when comparing mocktransduced LLC (LLCMock) with LLCSULT2B1b (Fig. 2, D and F) , and the LXR ligandreleasing AB1Mock with AB1SULT2B1b mesotheliomas grown orthotopically in the peritoneal cavity ( Fig. 2 G 
and not depicted).
CD11b high Gr1 high cells are continuously recruited to tumor sites To understand whether the accumulation of these cells was a result of local proliferation or of their continuous recruit ment from circulation, we performed parabiosis experiments, joining CD45.1 + and CD45.2 + mice by surgery to establish common blood circulation (Wright et al., 2001 ; Fig. 3 A) . 7 d after RMA challenge in CD45.2 + mice, we separated the mice and analyzed tumor infiltrating cell chimerism by FACS (Fig. 3 A) . As early as 2 d after separation, we observed a nearly during MS chemical ionization, as reported at http://www .lipidmaps.org. The analysis of hydroxycholesterol extracts from control medium or from NIH3T3 and RMACM showed the same qualitative fragmentation pattern (Fig. 1, B and C), Migration of CD11b high Gr1 high bona fide neutrophils toward oxysterols is mediated by G protein-coupled receptors (GPCRs) and does not require LXR signaling To characterize the population of myeloid cells migrating to 22RHC, we took advantage of the in vitro migration assay. Thus, we compared phenotype and morphology of BMderived migrating (CD11b high Gr1 high ) and nonmigrating (CD11b + Gr1 + ) cells, collected from the lower and upper chamber of migra tion transwells, respectively (Fig. S1 A) . Morphological and cytochemical analyses of the migrating cells showed the pres ence of nuclei similar to immature granulocytes and mature neutrophils (Fridlender et al., 2009; unpublished data) . FACS analysis showed that these cells express Ly6G + and Ly6b + markers typical of immature/mature neutrophils (Fig. S1 B) , whereas nonmigrating CD11b + Gr1 + cells were phenotypi cally different (Fig. S1 C) . Additionally, CD11b high Gr1 high cells expressed higher levels of CCR1, CXCR4, and CXCR2 chemokine receptors than CD11b + Gr1 + cells, as expected for neutrophils (Fig. S1 , B and C). In agreement, neutrophils pu rified from bone marrow by standard methods (Corada et al., 2005) migrated to synthetic and tumorderived LXR ligands in vitro and in vivo (unpublished data).
As the synthetic LXR ligand T1317 was not capable of triggering cell migration in vitro (Fig. 4 C) , we asked whether LXR signaling was, indeed, involved in this migration. CD11b high Gr1 high Ly6G + cells from Lxr / ,  / , and  / mice (Alberti et al., 2001 ) migrated to 22RHC as well as wild type cells, indicating that LXR signaling is not required for their migration (Fig. 5 A) . The prototypic receptors involved in leu kocyte migration belong to the GPCR superfamily (Rossi and Zlotnik, 2000) and can be inhibited by pertussis toxin (PTX). PTX inhibited the migration of CD11b high Gr1 high Ly6G + cells to 22RHC, thus demonstrating that a GPCR is responsible for the migration of these cells toward LXR ligands (Fig. 5 B) . (Fig. 4 A) . To identify the migrating subset of BM cells, we purified and tested the CD11b + and CD11b  populations. Migratory cells were in the CD11b + cell fraction (Fig. 4 B and not depicted). We observed by FACS analysis that nonmigrating cells co expressed CD11b and Gr1 markers at intermediate levels (CD11b + Gr1 + cells), whereas migrating cells were CD11b high Gr1 high (Fig. S1 A) , resembling the cell population detected in vivo within the tumors (Fig. 2 A) . Among the other oxy sterols tested, 24SHC, 27HC, 19HC, and 25HC also in duced cell migration (Fig. 4 C) . On the contrary, cholesterol, some sterolderived nuclear receptor ligands, and the syn thetic LXR ligand T0901317 (T1317) were unable to induce cell migration (Fig. 4, C and D) .
To prove that tumorderived LXR ligands were involved in the migration of CD11b high Gr1 high cells in vivo, we in jected total BM cells previously labeled with the fluorescent dye CFSE (CFSE + CD45.2 + ) in NODSCID mice bearing RMAMock or RMASULT2B1b. 18 h later, we analyzed tu mors for the presence of injected cells (CFSE + ) and found a higher percentage and number of exogenous (CFSE + CD45.2 + ) CD11b high Gr1 high cells infiltrating RMAMock, as com pared with RMASULT2B1b tumors (Fig. 4 , F and G, bot tom). As expected, the endogenous (CD45.1 + ) CD11b high Gr1 high cells were also more abundant in RMAMock (Fig. 4 , E and G, top). neutrophils with 22RHC induced the heterologous desensiti zation of the cells to the subsequent response to CXCL5 but did not affect the migration to CXCL12 (Fig. 5 C) . These results suggest that 22RHC and CXCL5 may share the same chemotactic receptor, namely CXCR2. Accordingly, heterolo gous desensitization of BMderived neutrophils with CXCL5 mediated by the CXCL12-CXCR4 and CXCL5-CXCR2 axes (Yang et al., 2008) . We therefore performed a migration assay toward 22RHC, CXCL5, CXCL12, and CCL3, a ligand of CCR1. BMderived neutrophils migrated to 22RHC, CXCL5, and SDF1, whereas migration to MIP1 was neg ligible (Fig. 5 C) . In addition, the pretreatment of BMderived involved in the migration of BMderived neutrophils toward 22RHC (Fig. 5 F) .
To investigate the role of the oxysterol-CXCR2 axis in neutrophil recruitment in vivo, we performed matrigel plug experiments. To distinguish neutrophil migration induced by 22RHC from that induced by other CXCR2binding che mokines that are locally released during the inflammation in duced by matrigel inoculation, we injected mice with matrigel or their treatment with the CXCR2 antagonist SB225002 (White et al., 1998) inhibited their migration to CXCL5 and to 22RHC (Fig. 5, D and E) . To finally prove the role of the CXCR2 receptor, we performed migration ex periments using BMderived neutrophils from Cxcr2 / mice (Cacalano et al., 1994) . These cells did not migrate to either CXCL5 or 22RHC, whereas they migrated to SDF1, demonstrating that CXCR2 is indeed the receptor Results are representative of four experiments. **, P < 0.01; ***, P < 0.0005. (D and E) Migration of CXCL5 (E) or SB225002 (F) pretreated CD11b + Gr1 + cells to 15 µM 22R-HC or 100 ng CXCL5 (mean ± SEM). Results are representative of two experiments. *, P < 0.05; **, P < 0.01. (F) Migration of WT, Cxcr2 +/ , and Cxcr2 / CD11b + Gr1 + cells to 15 µM 22R-HC, or 100 ng CXCL5 or CXCL12 (mean ± SEM). Results are representative of four experiments. **, P < 0.01; ***, P < 0.0001.
Oxysterol-migrating neutrophils favor tumor growth by promoting neoangiogenesis or immunosuppression
Because the inactivation of oxysterols by SULT2B1bex pressing tumors induces tumor growth delay or rejection (Villablanca et al., 2010) , we hypothesized that neutrophils recruited by tumorderived oxysterols could exert protu mor activities (i.e., immunosuppression and/or neoangio genesis), as already reported by others (Yang et al., 2004; Nozawa et al., 2006; Fridlender et al., 2009) . Therefore, we investigated the protumor functions of 22RHC-migrating plugs containing CXCL5, 22RHC, or 22SHC alone or in the presence of antiCXCL1, 3, 5, and 7 mAbs (Fig. 6 A) . 5 h later, plugs were analyzed for the presence of CD11b + Ly6G + neu trophils (Fig. 6 A) . CXCL5 and 22RHC induced a high recruitment of neutrophils, whereas 22SHC behaved as matri gel alone (Fig. 6 A) . AntiCXCL mAbs almost completely in hibited migration induced by CXCL5 (88.6% inhibition) and 22SHC (80% inhibition), whereas 22RHC-induced migra tion was only partly inhibited (48.3% inhibition) (Fig. 6 A) , indicating that 22RHC is indeed able to recruit neutrophils in vivo. Accordingly, the percentage of neutrophil infiltration in RMAMock and RMASULT2B1b (Fig. 2 C) correlated with the availability of active oxysterols, but not with the con tent of CXCL1 and CXCL5 chemokines detected within the tumor, as shown by quantitative analyses reporting higher lev els of CXCL1 and CXCL5 chemokines in RMASULT2B1b than in RMAMock (Fig. 6 , B and C). 22RHC-induced migration was mediated by CXCR2, as it was inhibited when mice bearing 22RHC-embedded plugs were treated with the CXCR2 antagonist SB225002 (Fig. 6 D) . Finally, in vivo neutrophil migration was also independent of LXR signaling, as demonstrated by the migration of Lxr / neutrophils toward 22RHC-embedded matrigel plugs (Fig. 6 E) .
The engagement and activation of CXCR2 by 22RHC was demonstrated by three experimental approaches. First, 22RHC was able to induce CXCR2 downregulation, as evaluated by FACS analysis (Fig. 7 A) . Second, in a concentra tiondependent manner, 22RHC stimulated the binding of 35 SGTPS to membranes from CXCR2expressing L1.2 cells, but not from MockL1.2 cells, with an EC 50 value of 1.32 ± 0.25 µM (Fig. 7, B and C) . On the contrary, 22SHC did not activate any 35 SGTPS binding, suggesting that this oxysterol does not interact with CXCR2 (Fig. 7 , B and C). As expected, the natural CXCR2 ligand IL8 stimulated 35 SGTPS binding, with an EC 50 of 2.50 ± 0.17 nM (Fig. 7 B) . Furthermore, we observed a dosedependent inhibition of 35 SGTPS binding when 22RHC was displaced by increas ing concentrations of the CXCR2 antagonist SB225002 (Fig. 7 D) . Third, 22RHC inhibited the cAMP formation elicited by 1 µM forskolin in a dosedependent manner, with an EC 50 value of 1.32 ± 0.25 µM in CXCR2expressing CHOK1 but not in MockCHOK1 cells (Fig. 7, D and E ). Yet in this system, the CXCR2 antagonist SB225002 coun teracted the inhibition of cAMP formation elicited by 10 µM 22RHC in a dosedependent manner (unpublished data). Notably, the EC 50 values of 22RHC-CXCR2 interactions that we detected (1.32 µM) are in the same range as those re ported for 22RHC-LXR activation (1.5 µM; Janowski et al., 1996) , indicating that 22RHC oxysterol is able to activate both LXRs and CXCR2 with a similar potency.
Additionally, 22RHC and 25HC displaced 125 IIL8 from CXCR2expressing cells in a dosedependent manner (Fig. 7 G) , whereas 22SHC and 4HC (two oxysterols un able to promote cell migration, Fig. 4 C) did not (unpublished data), thus suggesting that 22RHC, 25HC and IL8 could bind the same domain of CXCR2. neutrophils in vitro and in vivo in RMA, AB1, and LLC tumor models.
In vitro, BMderived 22RHC-migrating neutrophils (CD11b high Gr1 high ) were unable to suppress both the priming (Fig. 8 A) and the restimulation (Fig. 8 B) of OVAspecific OTI T cells. However, they released a high amount of total MMP9 (Nozawa et al., 2006;  Fig. 8 C) , expressed high mRNA levels of the proangiogenic factor Bv8 (Shojaei et al., 2008 ; Fig. 8 D) , and released Bv8 when exposed for 18 h to tumor CM (Fig. 8 E) .
In vivo, we tested whether RMAinfiltrating neutrophils were endowed with immunosuppressive functions, as neu trophils may acquire an immunosuppressive ability within the tumor microenvironment (Fridlender et al., 2009; De Santo et al., 2010) . However, we failed to detect any sup pression of OTI T cell activation (Fig. 8 F) . In agreement with the reported in vitro proangiogenic functions, we ob served an increased number of abnormal CD31 + vessels by immunohistochemistry (Fig. 8 G) and a higher percent age of CD45  CD31 + cells in 6d established matrigel plugs containing RMA (Fig. 8 H) or B16F1 (not depicted) ad mixed with 22RHC-migrating CD11b high Gr1 high neutro phils. These results paralleled the increased tumor weight we observed when RMA tumors were admixed with 22RHC-migrating CD11b high Gr1 high neutrophils (Fig. 8 I) . In contrast, we observed tumor growth delay, decrease of neutrophil but not of CD11b + Gr1 + cell infiltration, and reduction of CD45  CD31 + endothelial cells when we treated RMA bearing mice intratumor with an antiGr1 mAb (Fig. 9, A-C; and not depicted). To investigate the role of CXCR2 receptor activation in vivo and to mimic a possible pharmacologic antitumor therapy, we treated RMAbearing mice with the CXCR2 antagonist SB225002 and found a significant delay of RMA growth (Fig. 9 D) . However, as in the tumor microenviron ment, CXCR2 is expressed by neutrophils and at lower levels (unpublished data) by some mature endothelial cells (Strieter et al., 2006) , and we performed tumor growth experiments in wildtype and in Cxcr2 / bone marrow chimera to distinguish the role of the two cell populations. SB225002 significantly delayed tumor growth in wildtype but not in Cxcr2 / chi mera mice (Fig. 9 E) . Moreover, in these tumors we detected a reduced percentage of neutrophils and CD45  CD31 + en dothelial cells (Fig. 9, F and G) , thus demonstrating that in the RMA tumor model, tumorreleased oxysterols favor tumor growth by recruiting proangiogenic neutrophils. Whether oxysterols may also have an effect on BMderived endothelial progenitor cells expressing CXCR2 deserves a deeper inves tigation in suitable tumor models (Shaked et al., 2008) .
As reported above, we also investigated the possible protu mor role of oxysterolrecruited neutrophils in AB1 and LLC tumor models. We observed a reduced number of perito neal tumor nodules associated with a reduction of neutro phils and CD45  CD31 + endothelial cells when we treated AB1bearing mice with the CXCR2 antagonist SB225002 (Fig. 10, A-C) . Similar results were obtained by inactivating oxysterols with SULT2B1b. Indeed, we observed a lower number of peritoneal tumor nodules and prolonged survival of mice bearing AB1SULT2B1b as compared with mice bearing AB1Mock tumors (not depicted and Fig. 10 D) . The prolonged survival was associated with a lower percentage of infiltrating neutrophils (Fig. 2 G) and CD45  CD31 + endo thelial cells (Fig. 10 E) .
In the LLC tumor model, we also observed a significant growth delay when we treated tumorbearing mice with SB225002 ( Fig. 10 F) and when LLC was grown in Cxcr2 / bone marrow chimera mice (Fig. 10 G) . In this experimental setting, tumor growth delay paralleled the reduction of neu trophil infiltration (Fig. 10 H) . However, we failed to detect any difference in the percentage of CD45  CD31 + cells be tween LLC tumors from wildtype and Cxcr2 / chimera mice (Fig. 10 I) . Similar results were obtained when BM derived neutrophils were coinjected in matrigel admixed with LLC tumor cells (Fig. 10 J) . These results suggest that mechanisms different from those acting in the RMA and AB1 tumors are responsible for tumor promotion by neutrophils in LLC tumor, such as immune suppression. Indeed, neutro phils purified from LLC tumors were able to suppress OTI T cell activation (Fig. 10 K) , thus indicating that in this tumor model, neutrophils mainly exert their protumori genic activity by the immune suppression of antitumor im mune responses.
Altogether, these results indicate that some tumorderived oxysterols recruit neutrophils in a CXCR2dependent man ner, which in turn exploit (i.e., neoangiogenesis) or acquire (i.e., immune suppression) protumor activities, thus favoring tumorigenesis. The inactivation of the oxysterol-CXCR2-neutrophil axis is able to effectively counteract tumor growth.
DISCUSSION
In recent years, bone marrow-derived immature and mature myeloid cells have been extensively investigated, as they are endowed with a high capability to exert protumor functions (Gabrilovich et al., 2012) . Indeed, these cells can suppress antigenspecific immune responses (immature myeloid cells or myeloidderived suppressor cells), exert a proangiogenic activity (immature myeloid cells or neutrophils; Murdoch et al., 2008; Motz and Coukos, 2011) , or induce chemoresis tance and invasion or metastasis (immature myeloid cells; Yang et al., 2008; Acharyya et al., 2012) . These cells are recruited to tumor microenvironment mainly by chemokines constitu tively released by tumor and stromal cells Qian et al., 2011; Acharyya et al., 2012) or produced after some aggressive treatments (Kerbel, 2008) . Our study highlights an unanticipated role of tumorderived oxysterols/ LXR ligands, which contribute to the recruitment of protu mor neutrophils in a CXCR2dependent manner, ultimately favoring tumor growth.
The migration of neutrophils to the oxysterol 22RHC did not require LXR signaling because it occurred also with neutrophils from Lxr / ,  / , and  / mice but re quired the functional interaction with the GPCR CXCR2, as demonstrated by the 22RHC-mediated activation of 35 SGTPS binding and by the inhibition of cAMP forma tion elicited by forskolin stimulation. The interaction between oxysterols and GPCRs has recently been described to occur for the oxysterol 7,25HC, which specifically binds EBI2 but not LXRs (Hannedouche et al., 2011) . The CXCR2 activating oxysterols identified by our study have been pri marily reported to bind LXRs (Janowski et al., 1996) . However, the EC 50 values of CXCR2/22R-HC interaction we measured (1.32 µM) turned out to be very similar to those reported by Janowski et al. (1996) for LXR/22R-HC inter action (1.5 µM). In this context, our results are in agreement with a recent in vitro study showing that the oxysterol 20SHC activates the 7transmembrane oncoprotein smoothened, in addition to LXRs, with a similar potency (i.e., 3 µM for smoothened, and 4-7 µM for LXR; Nachtergaele et al., 2012) . Notably, Nachtergaele et al. (2012) reported that the oxysterol 20SHC could act as allosteric modulator of protein binding. Instead, in our system we did not observe any syner gistic effect when neutrophils were allowed to migrate in vitro toward mixtures of 22RHC and CXCR2 ligands (unpub lished data). Altogether, these observations identify the oxy sterols as molecules endowed with a broad range of activity (i.e., binding to LXRs and/or to other receptors) depend ing on the tissue and the pathophysiologic conditions of the microenvironment in which they are produced. Indeed, in our tumor models, the dual role of oxysterols, i.e., the CXCR2mediated recruitment of protumorigenic neutro phils and the recently described LXRdependent dampening of DC migration (Villablanca et al., 2010) , coexists and adds up to promote tumor growth. This is confirmed by tumor growth experiments in Lxr / bone marrow chimera mice, in which the growth rate of the oxysterolreleasing RMAMock is, how ever, higher than that of RMASULT2B1b, where the oxyste rols are inactivated (unpublished data). Notably, in our tumor model LXR does not seem to play a major role, as RMA Mock showed the same growth rate in Lxr / and wild type bone marrow chimera mice (unpublished data). The identification of oxysterols (22RHC, 20SHC, etc.) endowed with the promiscuous ability to activate two different recep tors highlights the need to carefully investigate these mole cules to identify new biological functions associated with oxysterols in different physiological and pathological condi tions, including tumors.
The in vivo experiments using 22RHC-embedded matrigel plugs indicate that oxysterols may contribute, to gether with CXCL chemokines (Fig. 6 A) , to neutrophil re cruitment within tumor microenvironment, as indicated by the detection of higher numbers of neutrophils in oxysterol releasing tumors. These results are further corroborated by the observation that the percentage of neutrophil infiltration cor related with the availability of active oxysterols, but not with the content of CXCL1 and CXCL5 chemokines detected within the tumor (Fig. 6, B and C) . Recently, different mo lecular mechanisms able to modify protein structure within tumors (Nagaraj et al., 2007; Molon et al., 2011) or in dam aged tissues (Venereau et al., 2012) have been reported. Par ticularly, protein nitration has been demonstrated to modify the chemotactic capacity of chemokines present in tumors. In this context, the chemoattractant ability of oxysterols might play a relevant role in the tumor microenvironment, in which chemokines could be structurally and functionally altered (Molon et al., 2011) . Whether, this mechanism is also relevant for the recruitment of immune cells in some phases of physi ological inflammatory processes (i.e., wound healing) will re quire further studies.
We report that RMA tumor cells produce 22RHC and 27HC oxysterols and other species that we are characteriz ing (Fig. 1 G) , whereas LLC tumor cells produce 24SHC (not depicted). However, a clear picture of how and when oxysterols are produced within tumor microenvironment re mains elusive. RMA and LLC constitutively express transcripts for the oxysterolgenerating enzymes Cyp11a1, Cyp27a1, and Cyp46a1 ( Fig. 1 H and unpublished data ; Björkhem, 2002; Mast et al., 2011) . However, a nonenzymatic pathway, involv ing reactive oxygen species that are frequently increased in the tumor microenvironment (Murphy and Johnson, 2008) , can also participate in oxysterol generation, further contribut ing to the production and accumulation of oxysterols in vivo. Moreover, recent studies reveal additional complexity. In deed, other cells of the microenvironment have been reported to express oxysterolproducing enzymes and to generate oxysterols (Diczfalusy et al., 2009; Yi et al., 2012) . Because tumor microenvironment is a complex tissue, in which all the cells described so far to generate oxysterols are present (tumor cells, stromal cells, and immune cells), we speculate that appropriate mouse models are needed to investigate the rela tive contribution of oxysterolproducing cells within tumors. The investigation of cells and factors regulating oxysterol pro duction should clarify in the near future the mechanisms re sponsible for oxysterol generation, their overall contribution to tumorigenesis, and possibly identify drugs capable of in hibiting their in vivo generation.
The demonstration that some freshly isolated human tumor cells release oxysterols able to bind both LXR and CXCR2 (Fig. 1 I and J; and not depicted), along with the observation that higher numbers of intratumor neutrophils severely affect overall survival of kidney cancer patients (Jensen et al., 2009) , suggests that manipulating LXR ligands and their interaction with CXCR2 and immune cells could provide additional targets for the development of new anti tumor therapies.
MATERIALS AND METHODS
Animal studies and reagents. C57BL/6 CD45.1 or CD45.2, Balb/C and NODSCID mice were from Charles River and Harlan. Cxcr2 +/ and Cxcr2 / mice were from The Jackson Laboratory. Lxr / knockout mice were generated as described previously (Alberti et al., 2001 ). Mice were maintained in the pathogenfree facility of San Raffaele Scientific Institute. Experiments were conducted in compliance with the Institutional Animal Care and Use Committee program (IACUC no. 341 and 436). Most anti bodies were from BD. CXCL5, CXCL12, CCL3, and IL8 were from R&D Systems. 22RHC, 22SHC, 25HC, 24,25 Epoxycholesterol, 7HC, Cho lesterol, chenodeoxycolic acid, and GlycoCDCA were from SigmaAldrich and from Avanti Polar Lipids. 24HC, 27HC, 4HC, and 7HC were from Avanti Polar Lipids. 19HC was from Santa Cruz Biotechnology, Inc. T0901317 and Pregnenolone were from Cayman. CFSE was used at 4 µM (Molecular Probes). PTX and PTX BOligomer were from Enzo Life Sci ences. Rat anti-mouse CD11b MicroBeads were from Miltenyi Biotec. SB225002 was from Tocris. Dead Cell Stain kit (Live/Dead Fixable Far red) was from Invitrogen. Buthlyhydroxytoluene (BHT) and solvents of HPLC grade were obtained from SigmaAldrich. The C18 cartridges (360 mg) were obtained from Waters Chromatography EUROPE (Netherlands).
Promoter reporter assay for nuclear receptor activity. We transfected 10 5 HEK293 cells/well with 100 ng of the plasmid pMH100X4TK luc/well together with 100 ng/well pCMXGal4LXR plasmid using FuGene 6 Transfection Reagent (Roche). 4 h after transfection, we treated the cells with tumor CM for 24 h. Luciferase activity was evaluated by Luciferase Reporter Assay Systems (Promega) according to the manufacturer's pro tocol. We used 30 ng galactosidase/well for transfection normalization (Villablanca et al., 2010) .
Sample collection and solid-phase extraction of hydroxycholesterols. All the cell lines analyzed were seeded at 10 5 cells/ml and cultured for 48 h. Then, conditioned media were collected, added to butylhydroxytolu ene (40 µM final concentration) to avoid cholesterol oxidation (Gilardi et al., 2009) , and stored at 80°C until processing. Hydroxycholesterol extraction was made as previously described (Burkard et al., 2004) . In brief, the C18 cartridges were preconditioned with 1 ml nheptane/2propanol (50:50, vol/vol), 1 ml methanol, and 2 ml of water. 2 ml of the cellfree medium was then applied to the cartridge using only gravity. Afterward, the cartridge was washed with 4 ml methanolwater (75:25, vol/vol) and briefly dried under vacuum. Hydroxysterols were desorbed with 2 ml nheptane/2propanol (50:50, vol/vol) using only gravity. The eluted substances were dried at 30°C by evaporation (Rotavapor), and the residue was dissolved in 200 µl of meth anol and subjected to CIMS analysis and HPLC analysis.
MS analysis.
MS was performed on a Thermo Electron TRACE DSQTM spectrometer through the rapid heating filament DirectExposure Probe (DEP) insertion mode. The MS analyses were performed in chemical ioniza tion (CIMS) using methane as reactant gas at an electron energy of 70 eV with a source temperature of 200°C.
High performance liquid chromatography (HPLC). An HPLC method was developed based on the HPLCESIMS methods described in McDonald et al. (2007) . Hydroxycholesterols were resolved using reverse phase HPLC (RPHPLC) equipped with a Waters 996 Photodiode Array Detector (wavelength 213 nm). A 100 µl aliquot of lipid extract (in methanol) or standard solution was loaded onto a RPHPLC column (5 µm, 250 × 4 mm LiChrospher 100 RP18 column; Merck) equipped with a guard column. Elution of hydroxycholesterols was performed at flow rate of 300 µl/min, with a gradient formed by the solvent system A, consisting of methanol/ water (85:15, vol/vol) and solvent system B consisting of methanol, both containing 5mM ammonium acetate. The gradient elution program was as follows: for RMACM analysis, 3 min with solvent A, 33 min with a linear gradient from 100% solvent A to 100% solvent B, 15 min with 100% solvent B, 5 min with a linear gradient from 100% solvent B to 100% solvent A; for all the other CM analyzed, 3 min with solvent A, 55 min with a linear gradi ent from 100% solvent A to 100% solvent B, 10 min with 100% solvent B, 5 min with a linear gradient from 100% solvent B to 100% solvent A, and maintained for 10 min to reequilibrate the column before the next run.
Chemotaxis assay. Chemotaxis assays were performed using 5µm pore polycarbonate filters in a 24well transwell chamber (Corning Costar Cor poration). Total bone marrow or CD11b + purified cells (2 × 10 5 /100 µl) were seeded in the upper chamber, whereas in the lower chamber 600 µl of medium (RPMI 0.5% BSA) containing 15 µM 22RHC or 22SHC or 100 ng CXCL5, CXCL12, CCL3, or IL8. 2 h later, migrated cells were measured by flow cytometer acquisition of a fixed number of beads (10,000/sample; Poly sciences). GPCR involvement was investigated by pretreating the cells for 90 min at 37°C with 500 ng PTX. Desensitization experiments were per formed by pretreating the cells for 3045 min at room temperature with 50 µM 22RHC or 2 µg/ml CXCL5. 500 ng PTX BOligomer was used as control of PTX inhibition. Experiments with SB225002 were performed treating the cells with 20 µM SB225002 before migration. Results of migra tion experiments were calculated as described previously (Villablanca et al., 2010) . Spontaneous migration was always subtracted with the exception of the experiments reported in Fig. 2 (C and D) .
Analysis of tumor-infiltrating cells. RMAMock, RMASULT2B1b, LLCMock, and LLCSULT2B1b tumors have been described previously (Villablanca et al., 2010) . AB1Mock and AB1SULT2B1b were obtained by engineering AB1 cells with lentivirus encoding SULT2B1b or empty vector as described previously (Villablanca et al., 2010) . Tumors collected 14-15 d after injection were cut into small fragments and digested for 4560 min at 37°C with 1.4 mg/ml collagenase A, B, and D (Roche) and 40 µg/ml DNase (Roche) mixture in RPMI medium with 10% FBS. Single cell suspensions were washed and labeled with Dead Cell Stain kit reagents for 30 min at 4°C. After washing, the cells were incubated for 5 min at RT with Fcblocking solution (10 µg/ml mouse Fc Block; BD) and labeled with CD11b, Gr1, CD45.1, or CD45.2 mAbs. Samples were run by FACSCalibur flow cytom eter (BD) and analyzed by FlowJo software gating on live cells. 10 µM 22R HC or 22SHC were administered every 2 d intratumor. After 14 d, collected cells were analyzed as described above.
Real-time RT-PCR experiments.
Myeloid cells (immature and mature) were purified by percoll gradients from bone marrow of wildtype mice, or mice injected with RMAMock or RMASULT2B1b. Total RNA was isolated with TRIZOL (Invitrogen). Reverse transcription was per formed from 1-2 µg of total RNA, using MLVreverse transcription (In vitrogen). qRTPCR was performed using realtime PCR (ABI PRISM 7900; Applied Biosystems) and Sybr Green. The comparative Ct method was used to quantify transcripts normalized to cyclophillin as a gene refer ence. qRTPCR was performed using primers specific for the LXR target genes Abcg1 and Srebp-1c. Primers for Bv8 have been reported in Shojaei et al. (2007b) . Primers for Cyp11a1, Cyp27a1, and Ch25h are as follows: Cyp11a1 forward, 5AGAGTTTCCAAAAGTATGGCCC3; reverse, 5ATACTGGTGATAGGCCACCCAGG3. Cyp27a1 forward, 5GAC CTCCAGGTGCTGAAC3; reverse 5CTCCTGTCTCATCACTTG CTC3. Ch25h forward, 5CTGCCTGCTGCTCTTCGACA3; reverse, 5CCGACAGCCAGATGTTAATC3.
In vivo migration experiments. We injected NODSCID mice with RMAMock or RMASULT2B1b. 13-14 d later, we transferred 10 × 10 6 CFSElabeled total bone marrow cells into tumorbearing mice. 18 h later, tumors were processed as described before. The percentage and number of bone marrow-derived exogenous and endogenous CD11b high Gr1 high cells was evaluated by gating on CFSE + and CD45.1 + cells, respectively.
Parabiosis experiments. 6-8wkold sexmatched congenic C57BL/6 wildtype mice were joined at the flanks as described in Wright et al. (2001) . 3 d later, 5 × 10 5 RMA cells were injected s.c. in the flank of the CD45.2 mice. Mice were surgically separated 7, 4, and 2 d prior to collection of tumors and analysis.
Immunofluorescence, immunohistochemistry, and immunocytochemistry. For immunofluorescence, we used anti-CD11bFITC, biotinyl ated antiGr1 antibody revealed by streptavidin, Alexa Fluor 555 (Invitrogen), and DAPI. We embedded samples in OCT freezing medium and prepared tissue sections 7 mm thick, which were then fixed in 4% paraformaldehyde. Images were taken by the Eclipse i80 microscope (Nikon). For immuno histochemistry, tumor samples were embedded in optimal cutting tempera ture medium and frozen in liquid nitrogen. We stained 3µm paraffin sections with H&E for morphological analysis or immunostained them with rat anti CD31 mAb (Serotec), followed by a biotinylated conjugated ratspecific antibody (Biocare). Reactions were visualized with horseradish peroxidaseconjugated streptavidin and 3,3 diaminobenzidine as chromogen (Biogenex). Slides from LXR ligand migrating CD11b high Gr1 high cells were prepared by centrifugation at 1,500 rpm for 10 min in a Shandon Cytospin 3. Cells were stained using MayGrunwaldGiemsa and evaluated under light microscopy.
Matrigel plug assays. 300 µl matrigel containing 0.5 mM 22RHC or 0.5 mM 22SHC (100 µl) was injected subcutaneously into C57BL/6 mice. Plugs were removed after 5 h, digested for 1 h at 37°C with 1.8 U/ml Dip sase (Gibco), and analyzed by FACS as described above. 0.8 mM SB225002 was given intraperitoneally 2 d before matrigel injection. Matrigel contain ing CXCL5, 22RHC, or 22SHC alone or together with blocking anti bodies against mouse CXCL1, CXCL3, CXCL5, and CXCL7 chemokines (R&D Systems; 10 µg each) was injected subcutaneously into C57BL/6 mice. 5 h later, plugs were removed and analyzed as described above.
CXCL1 and CXCL5 ELISA assays. 7destablished RMAMock and RMASULT2B1b tumors were collected and digested mechanically and en zymatically up to single cell suspension. Cells were counted and plated in 24 well plates (10 6 cells/well in 1 ml). After 24 h, supernatants were collected and the content of CXCL1 and CXCL5 was measured according to the manufacturer's recommendations. CXCL1 and CXCL5 ELISA kits were from R&D Systems.
Viral vectors and transduction procedures.
The mCXCR2NGFr lentiviral transfer vector was generated by cloning the murine CXCR2 cDNA in place of the GFP into the selfinactivating hPGK.GFP.wPRE. mhCMV.NGFr.SV40PA lentiviral vector (AgeI-SalI sites). Concentrated VSVG-pseudotyped LV stocks were produced and titred as described previ ously (Villablanca et al., 2010) . L1.2 cells were transduced with 10 8 or 10 9 transduction units (TU)/ml VSVG-pseudotyped LV stocks, corresponding to 1.5 or 15 MOI (Villablanca et al., 2010) . Down-regulation of CXCR2. CD11b + cells were treated with 50 µM of 22RHC or 22SHC, 2 µg/ml CXCL5, 1 µg/ml SDF1, or 10 µM SB225002 for 30 min at room temperature. After washing, the cells were labeled with antiCD11b, antiGr1, and antiCXCR2 mAbs and run by FACS.
35 S-GTPS binding assay. Mock or CXCR2transduced L1.2 cells were homogenized in 5 mM Tris-HCl and 2 mM EDTA, pH 7.4, and centrifuged at 48,000 g for 15 min at 4°C. The resulting pellets (plasma membranes) were washed in 50 mM Tris-HCl and 10 mM MgCl 2 , pH 7.4, and stored at 80°C until use. The assay was performed as described in de Kruijf et al. (2011) with minor modifications. In brief, aliquots of control or 10 µg CXCR2expressing membranes were incubated in 96well plates in assay buffer (20 mM Hepes, 3 mM MgCl 2 , and 100 mM NaCl, pH 7.4) supple mented with 3 µM GDP, 0.15 nM 35 SGTPS (1,250 Ci/mmol; Perkin Elmer), and different compound concentrations (10-50 µM). 0.1-50 nM of the CXCR2 agonist IL8 was also assayed in parallel as a reference com pound. SB225002 antagonist was added for 5 min before the addition of IL8 or 22RHC to determine the inhibition of the agonistmediated G protein activation. After incubation at room temperature in a shaking water bath for 60 min, cells were harvested by rapid filtration and assayed for 35 S radioactiv ity. Nonspecific 35 SGTPS binding was measured with 50 µM GTPS. Analysis and graphic presentation of 35 SGTPS binding data were obtained by a nonlinear multipurpose curve fitting computer program (Prism; Graph Pad Software).
Measurement of cAMP levels. Intracellular cAMP levels were measured using a competitive binding method (Daniele et al., 2011) . In brief, mock or CXCR2transduced CHOK1 cells were seeded on 24well plates (48 × 10 3 cells/well) in 0.5 ml of medium. After 24 h, the entire medium was removed, and the cells were incubated at 37°C for 15 min with 0.4 ml DMEM in the presence of 20 µM of the phosphodiesterase inhibitor 4[(3butoxy4 methoxyphenyl)methyl]2imidazolidinone (Ro201724). The dose-response curve of tested ligands was evaluated by assessing their ability to inhibit cAMP accumulation stimulated by 1 µM forskolin. The compounds were added to cells for 15 min. When required, cells were preincubated for 10 min with SB225002 antagonist. The reaction was terminated by the removal of the medium and the addition of 200 µl of 0.4 N HCl. After 30 min, lysates were neutralized with 50 µl 4 N KOH, and the suspension was centrifuged at 800 g for 5 min. For the determination of cAMP production, the cAMP binding protein was incubated with 2 nM [ 3 H]cAMP and 50 µl of cell lysate or cAMP standard (0-16 pmol) at 0°C for 150 min in a total volume of 300 µl. The bound radioactivity was separated by rapid filtration through GF/C glass fiber filters (PerkinElmer Life and Analytical Sciences) and washed twice with 4 ml of 50 mM TrisHCl, pH 7.4. The radioactivity was measured by liquid scintillation spectrometry.
Receptor binding assay. Competition for the binding of 125 Ilabeled IL8 ([ 125 I]IL8; sp. act., 2,200 Ci/mmol; Perkin Elmer) to mouse L1.2 cells was conducted as described previously (Sozzani et al., 1997) . Mock or CXCR2 transduced L1.2 cells (0.8 × 10 6 /50 µl) in binding medium (RPMI 1640 with 1 mg/ml BSA) were incubated with 0.3 nM of labeled chemokine in the presence of 300 nM of unlabeled IL8 or 100 µM 22RHC, 25HC, 22SHC, or 4HC at 4°C for 2 h. Dosedependent inhibition experiments were performed by incubating the cells with 100, 50, 10, or 1 µM 22RHC or 22SHC. At the end of the incubation, cells were pelleted through a cush ion of oil by microcentrifugation. The radioactivity present in the tip of the tubes was evaluated using a gamma counter. Nonspecific binding to L1.2 mocktransduced cells was always subtracted for each condition described.
OT-I proliferation assay. Splenocytes from OTI mice were labeled with 4 µM CFSE. Then they were washed and pulsed for 1 h at 37°C with 2 µg/ml SIINFEKL peptide. LXR ligand migrating and nonmigrating CD11b + Gr1 + cells (10 5 or 5 × 10 4 ) were cultured in 96well roundbottomed plates with 2 × 10 5 CFSElabeled OTI splenocytes. 10 5 , 5 × 10 4 , and 2.5 × 10 4 tumorinfiltrating neutrophils were purified using Ly6Gmicrobeads (Miltenyi Biotec), analyzed by FACS (CD11b + Ly6G + were >90% of the cells), and then cultured in 96well roundbottomed plates with 2 × 10 5 CFSElabeled OTI splenocytes. Cells were analyzed 3 d later with a FACSCalibur flow cy tometer with FlowJo software. Data are presented as the percentage of prolif eration of SIINFEKLpulsed, CFSElabeled OTI splenocytes relative to the proliferation of SIINFEKLpulsed, CFSElabeled OTI splenocytes alone (set as 100%). To test OTI memory cells, we harvested OTI splenocytes from OTI mice previously immunized (10 d) with 5 µg SIINFEKL peptide emulsified in complete Freund's adjuvant.
Mouse total MMP-9 and Bv8 assays. 22RHC migrating and nonmi grating cells and fresh splenocytes (2 × 10 6 cells/ml) were plated in 24well plates. After 24 h, supernatants were collected and the content of total MMP9 was measured according to manufacturer's recommendations (mouse total MMP9; Quantikine; R&D Systems). For Bv8 ELISA assay, we plated 22RHC migrating and nonmigrating cells in 24well plates (3 × 10 6 cells/well in 1 ml) in the absence or in the presence of RMACM. After 24 h, superna tants were collected and the content of Bv8 was measured according to man ufacturer's recommendations (Bv8 ELISA kit; Uscn; Life Science! Inc.).
Angiogenesis assay. We injected mice with 2 × 10 5 RMA or LLC tumor cells alone or admixed with either 22RHC migrating CD11b high Gr1 high or nonmigrating CD11b + Gr1 + cells (10 5 ) resuspended in 100 µl PBS, mixed with 100 µl of matrigel. 6 d later, mice were sacrificed and matrigel plugs collected and digested with 1.4 mg/ml collagenase A, B, and D and 1.8 U/ml Dispase. Cell suspensions were labeled with Dead Cell Stain kit reagents for 30 min at 4°C. After washing, cells were incubated for 5 min at room tem perature with Fcblocking solution (10 µg/ml mouse Fc Block; BD) and la beled with CD31 and CD45 mAbs. We analyzed the samples by FACS (Mazzieri et al., 2011) and considered the endothelial cells as Dead  CD45  CD31 + cells. Experiments with B16F1 were performed by injecting 0.5 × 10 5 B16F1 cells alone or admixed with 5 × 10 5 BMpurified neutrophils.
Tumor challenge in wild-type, Cxcr2 / , Lxr / , or Lxr / chimera mice. C57BL/6 mice were injected subcutaneously with 1 × 10 5 RMA, 3 × 10 5 LLC, or intraperitoneally with 3 × 10 6 AB1 tumor cells. We evaluated tumor size by measuring perpendicular diameters by a caliper. For AB1 tumors, we evaluated overall survival and the number of peritoneal tumor nodules 14 d after tumor inoculation. Data are reported as the mean tumor volume ± SEM. We gave 0.8 mM SB225002 (Tocris) or DMSO in traperitoneally every 2 d, starting 5 d after tumor infusion. We gave 10 µM 22RHC intratumor every 2 d. We transplanted lethally irradiated (11 Gy) C57BL/6 mice with bone marrow of Cxcr2 / , Lxr / , Lxr / , or WT mice (5 × 10 6 bone marrow cells/mouse). 6-8 wk later, we challenged mice with RMA with or without SB225002, or with LLC. Cxcr2 / genotype was performed by PCR on splenocytes at the end of the experiments. Lxr / or Lxr / genotype was performed by PCR on blood cells before tumor challenge. Because Cxcr2 / chimera mice underwent death during the reconstitution phase, we treated transplanted mice with enrofloxacin for 15 d (7.5 mg/150 µl Baytril 5% solution in 300 ml of drinking water) ac cording to the indication of the veterinary staff of our spf facility.
Neutrophil depletion experiments. C57BL/6 mice were injected subcu taneously with RMA (1 × 10 5 ). 7 d later, we performed neutrophil depletion by intratumor injections of 30 µg of purified antiLy6G antibody 1A8 (Bio Legend) or rat IgG control antibody (Jackson ImmunoResearch Laborato ries, Inc.) twice per week, as described in Fridlender et al. (2009) . Tumor neutrophil depletion and angiogenesis were evaluated at the end of the tumor challenge by flow cytometry using antiCD11b, antiGr1, antiCD31, and antiCD45 mAbs. Tumor growth was analyzed as described above.
Statistical analysis. Data are expressed as mean ± SEM and were analyzed for significance by ANOVA with Dunnet's, Bonferroni's, or Tukey's multi ple comparison test, or by Student's t test. The analysis was performed with Prism software.
Online supplemental material. Fig. 1 shows the morphological and phe notypic characterization of gated 22RHC migrating and nonmigrating CD11b + Gr1 + cells. Online supplemental material is available at http://www .jem.org/cgi/content/full/jem.20130440/DC1.
